TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 0
Operating Income -221.6M
Net Income -221.7M
EPS (Diluted) $-2.17

Balance Sheet Metrics

Total Assets 458.9M
Total Liabilities 199.5M
Shareholders Equity 259.5M
Debt to Equity 0.77

Cash Flow Metrics

Operating Cash Flow -164.3M
Free Cash Flow -165.6M

Revenue & Profitability Trend

Biohaven Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i00000
Cost of Goods Sold i-----
Gross Profit i-----
Gross Margin % i0.0%0.0%0.0%0.0%0.0%
Operating Expenses
Research & Development i795.9M373.3M437.1M181.5M98.5M
Selling, General & Administrative i89.2M62.8M130.9M37.4M16.0M
Other Operating Expenses i-----
Total Operating Expenses i885.1M436.1M567.9M218.9M114.5M
Operating Income i-885.1M-436.1M-567.9M-218.9M-114.5M
Operating Margin % i0.0%0.0%0.0%0.0%0.0%
Non-Operating Items
Interest Income i-----
Interest Expense i-----
Other Non-Operating Income39.4M26.5M-1.9M6.5M-4.2M
Pre-tax Income i-845.7M-409.6M-569.8M-212.4M-118.7M
Income Tax i735.0K-1.4M438.0K1.4M0
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-846.4M-408.2M-570.3M-213.8M-118.7M
Net Margin % i0.0%0.0%0.0%0.0%0.0%
Key Metrics
EBITDA i-877.3M-429.1M-566.5M-217.5M-114.4M
EPS (Basic) i$-9.28$-5.73$-12.75$-5.97$-3.31
EPS (Diluted) i$-9.28$-5.73$-12.75$-5.97$-3.31
Basic Shares Outstanding i9123433771200527447413163582251135822511
Diluted Shares Outstanding i9123433771200527447413163582251135822511

Income Statement Trend

Biohaven Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i99.1M248.4M204.9M76.1M82.5M
Short-term Investments i386.9M133.4M260.5M0-
Accounts Receivable i-----
Inventory i-----
Other Current Assets508.0K12.1M19.3M2.1M10.0K
Total Current Assets i538.5M442.4M587.0M94.8M89.8M
Non-Current Assets
Property, Plant & Equipment i36.7M31.9M37.6M5.2M6.0M
Goodwill i21.2M21.2M21.2M21.2M0
Intangible Assets i18.4M18.4M18.4M18.4M-
Long-term Investments-----
Other Non-Current Assets3.1M2.4M2.6M3.2M1.0M
Total Non-Current Assets i76.6M70.8M74.8M47.2M21.7M
Total Assets i615.1M513.2M661.8M142.1M111.5M
Liabilities
Current Liabilities
Accounts Payable i18.0M15.6M10.7M4.8M2.8M
Short-term Debt i3.8M3.3M3.0M--
Current Portion of Long-term Debt-----
Other Current Liabilities84.7M-11.7M3.6M2.2M
Total Current Liabilities i154.2M55.4M90.0M41.9M29.9M
Non-Current Liabilities
Long-term Debt i32.8M27.6M30.6M2.8M-
Deferred Tax Liabilities i-----
Other Non-Current Liabilities4.7M2.2M2.4M2.6M4.8M
Total Non-Current Liabilities i37.4M29.8M33.0M5.4M4.8M
Total Liabilities i191.7M85.2M123.0M47.4M34.7M
Equity
Common Stock i1.7B887.5M615.7M0-
Retained Earnings i-1.3B-499.3M-91.1M0-
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i423.4M428.0M538.8M94.7M76.8M
Key Metrics
Total Debt i36.6M30.9M33.6M2.8M0
Working Capital i384.2M387.0M496.9M52.9M59.9M

Balance Sheet Composition

Biohaven Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-846.4M-408.2M-570.3M-213.8M-118.7M
Depreciation & Amortization i7.9M6.9M1.4M1.4M72.0K
Stock-Based Compensation i72.0M28.8M193.6M65.6M29.5M
Working Capital Changes i710.0K4.9M5.9M2.9M-3.5M
Operating Cash Flow i-694.1M-351.5M-273.2M-139.4M-92.6M
Investing Activities
Capital Expenditures i-4.0M-3.0M-6.1M-938.0K-2.7M
Acquisitions i-001.9M0
Investment Purchases i-745.7M-194.1M-263.7M00
Investment Sales i504.4M327.0M00-
Investing Cash Flow i-245.4M129.8M-269.8M944.0K-2.7M
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i-----
Debt Repayment i-----
Financing Cash Flow i666.3M211.9M767.6M138.4M152.2M
Free Cash Flow i-586.5M-334.8M-338.8M-146.8M-78.7M
Net Change in Cash i-273.2M-9.7M224.6M3.0K57.0M

Cash Flow Trend

Biohaven Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -1.70
Forward P/E -2.50
Price to Book 12.43
PEG Ratio 0.04

Profitability Ratios

Profit Margin 0.00%
Operating Margin 0.00%
Return on Equity -295.94%
Return on Assets -103.41%

Financial Health

Current Ratio 3.82
Debt to Equity 25.63
Beta 3.45

Per Share Data

EPS (TTM) $-7.46
Book Value per Share $1.27
Revenue per Share $0.00

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
bhvn1.7B-1.7012.43-295.94%0.00%25.63
Vertex 103.4B28.686.0222.77%31.86%8.89
Regeneron 63.8B15.132.0915.34%31.37%9.04
Vera Therapeutics 2.0B-10.964.11-54.84%0.00%16.56
Dyne Therapeutics 2.0B-3.882.61-61.32%0.00%21.19
Liquidia 1.9B-13.51126.72-389.13%58.00%1,319.26

Financial data is updated regularly. All figures are in the company's reporting currency.